Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

Biocon's stock price increased almost 4 per cent in the early trading session on 11 April after the company’s subsidiary ...

Biocon Biologics Ltd today announced that the U.S. FDA has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for ...

Biocon Biologics, a subsidiary of Biocon, has scored a major win with the U.S. FDA approving JOBEVNE (bevacizumab-nwgd), a biosimilar to Roche's blockbuster cancer drug Avastin.

Biocon Biologics (BBL), a subsidiary of Biocon, today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration ...